Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo BioSciences Licenses Protein Expression Technology to Novo Nordisk

NEW YORK, Sept. 7 (GenomeWeb News) - Sangamo BioSciences has licensed its zinc finger DNA-binding protein technology to Novo Nordisk, the companies said today.

 

Novo Nordisk, based in Bagsvaerd, Denmark, plans to evaluate the technology for enhanced protein production.

 

Sangamo, located in Richmond, Calif., said it has engineered zinc finger protein transcription factors that can increase protein production from genes.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.